AbbVie Inc. (ABBV) Deep Dive Video
Summary
AbbVie’s post-Humira transition is gaining traction, with 10% revenue growth, a 16.1x forward P/E, and substantial upside from pipeline execution.
View ABBV stock page · Read the ABBV research report
Loading the video player…